Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins

被引:0
作者
Kim, Kyeong Ok [1 ]
Lee, Si Hyung [1 ]
机构
[1] Yeungnam Univ, Coll Med, Dept Internal Med, 170 Hyeonchung Ro, Daegu 705717, South Korea
关键词
Integrin; Inflammatory bowel disease; Vedolizumab; Natalizumab; Etrolizumab; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INDUCTION THERAPY; CROHNS-DISEASE; VEDOLIZUMAB INDUCTION; MONOCLONAL-ANTIBODY; ALTERS TRAFFICKING; ENDOTHELIAL-CELLS; DOUBLE-BLIND;
D O I
10.4166/kjg.2024.070
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Recently, novel biologics or small molecular drugs have been introduced for overcoming the unmet needs associated with anti-tumor necrosis factor alpha agents for inflammtory bowel disease (IBD) treatment. Among these novel drugs, anti integrin agents block leukocyte trafficking to the intestine by blocking the interaction between integrin and cell adhesion molecules. Vedolizumab (anti-alpha 4137) is most widely used anti-integrin approved in both ulcerative colitis and Crohn's disease .It has been shown to be effective in both induction and maintenance therapy with a favorable safety profile due to gut selectivity. Several models incorporating clinical, genetic, immune and gut microbial markers to predict response to vedolizumab in IBD have been developed. Etrolizumab (anti-137) blocks leukocyte trafficking via alpha 4137 and cell adhesion via alpha E137 integrins. In addition, the introduction of subcutaneous vedolizumab showed similar efficacy and safety with improved patients' convenience. Other investigational anti-integrin therapies include abrilumab (anti-alpha 4137 IgG2), PN-943 (orally administered and gut-restricted alpha 4137 antagonist peptide), AJM300 (orally active small molecule inhibitor of alpha 4), and ontamalimab (anti-MAdCAM-1 IgG).
引用
收藏
页码:43 / 50
页数:8
相关论文
共 68 条
  • [1] One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
    Amiot, A.
    Serrero, M.
    Peyrin-Biroulet, L.
    Filippi, J.
    Pariente, B.
    Roblin, X.
    Buisson, A.
    Stefanescu, C.
    Trang-Poisson, C.
    Altwegg, R.
    Marteau, P.
    Vaysse, T.
    Bourrier, A.
    Nancey, S.
    Laharie, D.
    Allez, M.
    Savoye, G.
    Moreau, J.
    Vuitton, L.
    Viennot, S.
    Aubourg, A.
    Pelletier, A. -L.
    Bouguen, G.
    Abitbol, V.
    Gagniere, C.
    Bouhnik, Y.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) : 310 - 321
  • [2] Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
    Amiot, Aurelien
    Grimaud, Jean-Charles
    Peyrin-Biroulet, Laurent
    Filippi, Jerome
    Pariente, Benjamin
    Roblin, Xavier
    Buisson, Anthony
    Stefanescu, Carmen
    Trang-Poisson, Caroline
    Altwegg, Romain
    Marteau, Philippe
    Vaysse, Thibaud
    Bourrier, Anne
    Nancey, Stephane
    Laharie, David
    Allez, Matthieu
    Savoye, Guillaume
    Moreau, Jacques
    Gagniere, Charlotte
    Vuitton, Lucine
    Viennot, Stephanie
    Aubourg, Alexandre
    Pelletier, Anne-Laure
    Bouguen, Guillaume
    Abitbol, Vered
    Bouhnik, Yoram
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (11) : 1593 - +
  • [3] Molecular pathways controlling barrier function in IBD
    Atreya, Raja
    Neurath, Markus F.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2015, 12 (02) : 67 - 68
  • [4] Serum Interleukin-6 and-8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
    Bertani, Lorenzo
    Caviglia, Gian Paolo
    Antonioli, Luca
    Pellicano, Rinaldo
    Fagoonee, Sharmila
    Astegiano, Marco
    Saracco, Giorgio Maria
    Bugianesi, Elisabetta
    Blandizzi, Corrado
    Costa, Francesco
    Ribaldone, Davide Giuseppe
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [5] Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease
    Binion, DG
    West, GA
    Ina, K
    Ziats, NP
    Emancipator, SN
    Fiocchi, C
    [J]. GASTROENTEROLOGY, 1997, 112 (06) : 1895 - 1907
  • [6] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
    Bloomgren, Gary
    Richman, Sandra
    Hotermans, Christophe
    Subramanyam, Meena
    Goelz, Susan
    Natarajan, Amy
    Lee, Sophia
    Plavina, Tatiana
    Scanlon, James V.
    Sandrock, Alfred
    Bozic, Carmen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) : 1870 - 1880
  • [7] The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
    Cammarota, Giovanni
    Ianiro, Gianluca
    Cianci, Rossella
    Sibbo, Stefano
    Gasbarrini, Antonio
    Curro, Diego
    [J]. PHARMACOLOGY & THERAPEUTICS, 2015, 149 : 191 - 212
  • [8] Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study
    Choi, Su Jin
    Oh, Ji Seon
    Hong, Seokchan
    Lee, Chang-Keun
    Yoo, Bin
    Kim, Yong-Gil
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (03) : 723 - 731
  • [9] The safety of vedolizumab for ulcerative colitis and Crohn's disease
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Rutgeerts, Paul
    Sandborn, William
    Danese, Silvio
    D'Haens, Geert
    Panaccione, Remo
    Loftus, Edward V., Jr.
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Abhyankar, Brihad
    Feagan, Brian G.
    [J]. GUT, 2017, 66 (05) : 839 - 851
  • [10] Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+T Cells in Crohn's Disease: Report of the TOSCA Study
    D'Haens, Geert
    Vermeire, Severine
    Vogelsang, Harald
    Allez, Matthieu
    Desreumaux, Pierre
    Van Gossum, Andre
    Sandborn, William J.
    Baumgart, Daniel C.
    Ransohoff, Richard M.
    Comer, Gail M.
    Ahmad, Alaa
    Cataldi, Fabio
    Cheng, John
    Clare, Robert
    Gorelick, Kenneth J.
    Kaminski, Annamarie
    Pradhan, Vivek
    Rivers, Sunday
    Sikpi, Matthew O.
    Zhang, Yanhua
    Hassan-Zahraee, Mina
    Reinisch, Walter
    Stuve, Olaf
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 (02) : 188 - 196